Document Detail


The continual reassessment method in cancer phase I clinical trials: a simulation study.
MedLine Citation:
PMID:  8210815     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
In cancer studies, the aim of phase I clinical trials is to identify an appropriate dose for experimentation in phase II and III studies. The continual reassessment method (CRM) has been developed recently and presented as the method of choice in the design and analysis of such phase I studies. However, to implement the method, some methodological and practical considerations must be addressed. This paper examines, through a simulation study, the sensitivity of CRM both to the initial modelling of the dose-toxicity relationship and the prior. It appears that the performance of CRM can be improved by using vague priors and initial tuning of the model to allow flexibility.
Authors:
S Chevret
Related Documents :
12689735 - Estimating the distribution of nonterminal event time in the presence of mortality or i...
11297895 - Role of modelling and simulation in phase i drug development.
9750245 - Approaches for optimal sequential decision analysis in clinical trials.
20191605 - A confirmatory seamless phase ii/iii clinical trial design incorporating short-term end...
10877885 - Ecological constraints, life history traits and the evolution of cooperative breeding.
19709955 - A method for automatic fall detection of elderly people using floor vibrations and soun...
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  Statistics in medicine     Volume:  12     ISSN:  0277-6715     ISO Abbreviation:  Stat Med     Publication Date:  1993 Jun 
Date Detail:
Created Date:  1993-11-01     Completed Date:  1993-11-01     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8215016     Medline TA:  Stat Med     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  1093-108     Citation Subset:  IM    
Affiliation:
Département de Biostatistique et Informatique Médicale, Hôpital Saint-Louis, Paris, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antineoplastic Agents / administration & dosage*,  adverse effects,  toxicity
Bayes Theorem
Bias (Epidemiology)
Clinical Trials, Phase I as Topic* / methods,  standards
Dose-Response Relationship, Drug
Ethics, Medical
Evaluation Studies as Topic
Humans
Logistic Models
Models, Statistical*
Monte Carlo Method
Neoplasms / drug therapy*,  epidemiology
Organizational Objectives
Research Design*
Sensitivity and Specificity
Chemical
Reg. No./Substance:
0/Antineoplastic Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The nephritogenic T lymphocyte response in interstitial nephritis.
Next Document:  On population and individual bioequivalence.